Notiretatug rezetecan

Antibody–drug conjugate

Phase 3underway

Evidence outlook · registrational

Urothelial Carcinoma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2028-01-31.

Also in development:Non-Small Cell Lung Cancer · Phase 2HR+/HER2- Metastatic Breast Cancer · Phase 2Cervical Cancer · Phase 3

Featured evidence outside this drug's tracked markets:NCT06819319 · TNBC - Triple-Negative Breast Cancer · Phase 2 · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Cervical Cancer
Urothelial Carcinoma
Phase 2/3 (1)
Other / comorbidity
NCT06879145 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-04-25 – 2031-12 · Muscular Invasive Bladder Cancer (MIBC)
What this study did
Phase 2 (12)
HR+/HER2- Metastatic Breast Cancer
NCT06433609 · Beijing GoBroad Hospital
2024-08-05 – 2027-11 · Advanced Breast Cancer
What this study did
NCT06649331 · Fudan University
2024-10-21 – 2027-09 · Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Breast Cancer
What this study did
NCT07041437 · Fudan University
2025-06-30 – 2027-01-31 · Advanced Breast Cancer
What this study did
NCT05594095 · Fudan University
2022-12-30 – 2026-12-01 · Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07175220 · Jiangsu HengRui Medicine Co., Ltd.
2025-10-09 – 2028-10 · Locally Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06819319 · Henan Cancer Hospital
2025-06-23 – 2030-12-31 · TNBC - Triple-Negative Breast Cancer
What this study did
NCT06895928 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2025-03-28 – 2028-12 · Advanced Solid Tumors
What this study did
NCT06915142 · Shandong Suncadia Medicine Co., Ltd.
2025-04-28 – 2027-10 · Advanced Malignant Tumour
What this study did
NCT06547736 · Fudan University
2024-10-14 – 2027-06 · Pancreatic Cancer
What this study did
NCT05076682 · Fudan University
2022-06-30 – 2027-03-31 · Triple-negative Breast Cancer
What this study did
NCT06654440 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-11-15 – 2026-10-31 · Advanced Gynecological Malignancy
What this study did
Phase 1/2 (7)
Non-Small Cell Lung Cancer
NCT06512051 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-07-30 – 2026-10 · Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
NCT06589778 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-09-27 – 2026-04-30 · Non-Small Cell Lung Cancer
What this study did
Urothelial Carcinoma
NCT06639347 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-11-04 – 2027-05-31 · Advanced Urothelial Carcinoma
What this study did
Other / comorbidity
NCT06417554 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-05-27 – 2031-12-31 · Advanced Solid Tumors
What this study did
NCT07059221 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-07-11 – 2029-03 · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
NCT06955390 · Henan Cancer Hospital
2025-05-01 – 2026-12-01 · Solid Tumors
What this study did
NCT06474468 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-06-20 – 2026-10 · Advanced or Metastatic Esophageal Cancer
What this study did
Phase 1 (3)
Non-Small Cell Lung Cancer
NCT07414953 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2026-03-30 – 2028-11-30 · Lung Cancer
What this study did
Other / comorbidity
NCT05735275 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2023-03-03 – 2025-08-31 · Advanced Or Metastatic Solid Tumor Malignancies
What this study did
NCT05701709 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2023-04-06 – 2025-08-31 · Advanced Solid Tumors
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Cervical Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Notiretatug Rezetecan: this drugPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tisotumab Vedotin Humax-Tf-Adc (Tivdak)ApprovedAntibody–drug conjugateTissue Factor (TF)Partial signal
NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7)
NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4not yet gradedNo reviewed efficacy summary in this indication
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FamitinibPhase 3Small moleculec-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sutantatug EnvedotinPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
ALE.P02
Phase 1/2(overall)
Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(14 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Notiretatug rezetecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 2Advanced Malignant TumourRecruiting
Est. primary completion 2026-12 · NCT06915142 · CT.gov ↗
What to watch
Phase 2TNBC - Triple-Negative Breast CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT06819319 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT05076682 · CT.gov ↗
What to watch
2027 (6)
March 2027 (3)
Phase 1/2Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-03 · NCT07059221 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-03 · NCT06547736 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03 · NCT06433609 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-04-30 · NCT07414953 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1/2Urothelial CarcinomaRecruiting
Est. primary completion 2027-05-31 · NCT06639347 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3Cervical CancerRecruiting
Est. primary completion 2027-12 · NCT07418749 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
Phase 3Urothelial CarcinomaRecruiting
Est. primary completion 2028-01-31 · NCT07393542 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10 · NCT07175220 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Advanced Solid TumorsRecruiting
Est. primary completion 2028-12 · NCT06895928 · CT.gov ↗
What to watch
2031 (2)
December 2031 (2)
Phase 2/3Muscular Invasive Bladder Cancer (MIBC)Recruiting
Est. primary completion 2031-12 · NCT06879145 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2031-12-31 · NCT06417554 · CT.gov ↗
What to watch

See the full readout calendar ↗